Shopping Cart
- Remove All
Your shopping cart is currently empty
Cofetuzumab pelidotin
😃Good
Catalog No. T9901A-055Cas No. 1869937-48-3
Cofetuzumab pelidotin (PF-06647020) is an antibody-drug conjugate (ADC) targeting PTK7, composed of the humanized anti-PTK7 monoclonal antibody (hu6M024, IgG1) linked to the auristatin-based microtubule inhibitor payload, auristatin-0101 (Aur0101), via a cleavable valine-citrulline (vc)-based linker. This compound exhibits a drug-to-antibody ratio (DAR) of 4 and selectively binds to cell-surface PTK7 with an EC50 of 1153 pM as determined by flow cytometry. Cofetuzumab pelidotin holds promise for the study of solid tumors [1] [2] [3].
Cofetuzumab pelidotin
Cofetuzumab pelidotin
😃Good
Catalog No. T9901A-055Cas No. 1869937-48-3
Cofetuzumab pelidotin (PF-06647020) is an antibody-drug conjugate (ADC) targeting PTK7, composed of the humanized anti-PTK7 monoclonal antibody (hu6M024, IgG1) linked to the auristatin-based microtubule inhibitor payload, auristatin-0101 (Aur0101), via a cleavable valine-citrulline (vc)-based linker. This compound exhibits a drug-to-antibody ratio (DAR) of 4 and selectively binds to cell-surface PTK7 with an EC50 of 1153 pM as determined by flow cytometry. Cofetuzumab pelidotin holds promise for the study of solid tumors [1] [2] [3].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Cofetuzumab pelidotin"
Trastuzumab deruxtecan
VRN-101099, T-DXd, DS-8201a, DS 8201
T366461826843-81-5
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.
- $728
Size
QTY
Datopotamab deruxtecan
S-1062a, DS-1062, DS1062, Dato-DXd
T397302238831-60-0
Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.
- $1,060
Size
QTY
IMGC-936, IMGC936
T9901A-084
Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.
- $450
Size
QTY
Disitamab vedotin
RC-48, RC48, RC 48
T395952136633-23-1
Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.
- $347
Size
QTY
Glembatumumab vedotin
CR011-vcMMAE, CR 011 ADC, CDX-011
T741781182215-65-1
Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).
- $718
Size
QTY
Sacituzumab govitecan
IMMU-132
T778241491917-83-9
Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.
- $455
Size
QTY
Brentuximab vedotin
SGN-35
T76707914088-09-8
Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.
- $413
Size
QTY
Labetuzumab govitecan
Labetuzumab-SN38, IMMU-130, IMMU130, IMMU 130, hMN14-SN38
T255931469876-18-3
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.
- Inquiry Price
Size
QTY
Trastuzumab emtansine
T-DM1
T366471018448-65-1
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine, and is utilized in the investigation of advanced breast cancer[1][2].
- $1,320
Size
QTY
Zilovertamab vedotin
T77186
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate composed of the humanized monoclonal antibody zilovertamab linked to the anti-microtubule cytotoxin monomethyl auristatin E (MMAE). Upon binding to ROR1 on tumor cells, it is rapidly internalized and directed to lysosomes for cleavage, releasing MMAE and inducing apoptosis in targeted cells. Zilovertamab vedotin has potential applications in cancer research [1].
- Inquiry Price
Size
QTY
Cantuzumab ravtansine
T76940868747-45-9
Cantuzumab ravtansine (IMGN242; huC242-DM4), an antibody-drug conjugate (ADC), comprises the humanized monoclonal antibody huC242 covalently bonded through a disulfide linkage to the cytotoxic agent DM4 (DM4), demonstrating extensive antitumor effectiveness across various CanAg-positive human tumor xenografts [1] [2].
- Inquiry Price
Size
QTY
Cantuzumab mertansine
T76939400010-39-1
Cantuzumab mertansine (SB-408075; huC242-DM1), an antibody-drug conjugate (ADC), comprises the potent maytansine derivative (DM1) linked to the humanized monoclonal antibody (huC242) targeting CanAg. Demonstrating cytotoxicity against colon cancer cells, this compound shows extensive antitumor effectiveness across various CanAg-positive human tumor xenografts [1] [2].
- Inquiry Price
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Cofetuzumab pelidotin (PF-06647020) is an antibody-drug conjugate (ADC) targeting PTK7, composed of the humanized anti-PTK7 monoclonal antibody (hu6M024, IgG1) linked to the auristatin-based microtubule inhibitor payload, auristatin-0101 (Aur0101), via a cleavable valine-citrulline (vc)-based linker. This compound exhibits a drug-to-antibody ratio (DAR) of 4 and selectively binds to cell-surface PTK7 with an EC50 of 1153 pM as determined by flow cytometry. Cofetuzumab pelidotin holds promise for the study of solid tumors [1] [2] [3]. |
| In vitro | Cofetuzumab pelidotin (PF-06647020) exhibits cytotoxic effects in vitro against PTK7-expressing cancer cell lines H446, H661, and OVCAR3, with EC50 values of 7.6, 27.5, and 105 ng/mL, respectively[1]. Over a duration of six days, it shows high potency and PTK7-specific cytotoxicity in a range of cancer cell lines (A549, MDA-MB-468, KYSE-150, SKOV-3, PC9, NCI-H1975), with IC50 values ranging from 0 to 1100 nM[2]. However, its stability is relatively poor, with a T1/2 of less than 3 days[2]. |
| In vivo | Cofetuzumab pelidotin (PF-06647020; 3 mg/kg; intraperitoneal injection twice weekly for four cycles) demonstrated significant in vivo antitumor activity in patient-derived xenograft (PDX) models of NSCLC, OVCA, and TNBC [1]. The study utilized NOD scid mice aged 6 to 10 weeks, harboring cells from these cancers [1]. The findings confirm that the specified dosage and administration route effectively suppress these tumor cells. |
| Cas No. | 1869937-48-3 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Cofetuzumab pelidotin | purchase Cofetuzumab pelidotin | Cofetuzumab pelidotin cost | order Cofetuzumab pelidotin | Cofetuzumab pelidotin in vivo | Cofetuzumab pelidotin in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.